ValuEngine Lowers Agile Therapeutics (AGRX) to Sell

Share on StockTwits

Agile Therapeutics (NASDAQ:AGRX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday, ValuEngine reports.

Several other research analysts have also issued reports on AGRX. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Agile Therapeutics in a research report on Friday, January 11th. Maxim Group restated a “buy” rating and set a $3.00 target price on shares of Agile Therapeutics in a research report on Monday, February 11th. Finally, Janney Montgomery Scott started coverage on Agile Therapeutics in a research report on Friday, April 12th. They set a “buy” rating and a $4.00 target price for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $3.50.

Shares of NASDAQ AGRX opened at $1.48 on Wednesday. Agile Therapeutics has a 1-year low of $0.23 and a 1-year high of $2.97. The company has a market cap of $64.57 million, a price-to-earnings ratio of -2.55 and a beta of 0.45.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.02). On average, equities analysts predict that Agile Therapeutics will post -0.44 EPS for the current fiscal year.

In other Agile Therapeutics news, Director Abhijeet J. Lele acquired 20,000 shares of Agile Therapeutics stock in a transaction that occurred on Friday, March 29th. The stock was bought at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the purchase, the director now directly owns 37,949 shares of the company’s stock, valued at approximately $58,441.46. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Alfred Altomari acquired 25,000 shares of Agile Therapeutics stock in a transaction that occurred on Monday, March 25th. The stock was acquired at an average cost of $1.54 per share, with a total value of $38,500.00. Following the purchase, the chief executive officer now directly owns 238,568 shares of the company’s stock, valued at $367,394.72. The disclosure for this purchase can be found here. 7.30% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its position in shares of Agile Therapeutics by 54.3% during the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock worth $449,000 after purchasing an additional 430,907 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Agile Therapeutics by 260.7% during the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after purchasing an additional 226,255 shares in the last quarter. BlackRock Inc. increased its position in shares of Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 18,038 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 44,639 shares in the last quarter. 21.84% of the stock is owned by institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Further Reading: Net Income

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.